Eli Lilly Raises Forecast as Zepbound and Mounjaro Drive Record Sales

Eli Lilly has significantly raised its full-year outlook after reporting a blockbuster third quarter, fueled by surging demand for its weight-loss drugs Zepbound and Mounjaro. The pharmaceutical giant posted adjusted earnings of $7.02 per share, beating analyst expectations of $5.91, and revenue soared 54% year-over-year to $17.6 billion, driven largely by its GLP-1 treatments.

Sales of Mounjaro more than doubled to $6.52 billion, while Zepbound nearly tripled to $3.59 billion, both outperforming Wall Street forecasts. In response, Lilly raised its 2025 revenue guidance to $63 $63.5 billion, up from $60 $62 billion, and boosted its adjusted EPS forecast to $23 $23.70, previously $21.75 $23.

The company also announced a new partnership with Walmart to distribute Zepbound directly to patients, expanding access and reinforcing its dominance in the fast-growing obesity treatment market. With four successful Phase 3 trials for orforglipron, Lilly is preparing regulatory submissions for another obesity drug by year-end.

Eli Lilly’s stock climbed 2% following the announcement, reflecting investor confidence in its long-term growth trajectory. Analysts view the company’s aggressive expansion in the weight-loss segment as a strategic move to capture a multi-billion-dollar market projected to grow rapidly over the next decade.

Eli Lilly delivered a standout third-quarter performance, driven by explosive growth in its weight-loss treatments Mounjaro and Zepbound. The company reported:

• Adjusted EPS: $7.02 vs. $5.91 expected
• Revenue: $17.6 billion, up 54% year-over-year, beating the $16.06 billion forecast
• Mounjaro sales: $6.52 billion (vs. $5.41 billion expected)
• Zepbound sales: $3.59 billion (vs. $3.37 billion expected)

These results reflect the accelerating demand for GLP-1 therapies, which continue to reshape the obesity and diabetes treatment landscape. The strong performance prompted Eli Lilly to raise its full-year guidance, signaling confidence in sustained momentum.

The company also announced a partnership with Walmart to expand access to Zepbound, allowing patients to pick up prescriptions at Walmart pharmacies starting next month. This move is expected to further boost distribution and reinforce Lilly’s leadership in the weight-loss drug market.

Eli Lilly’s latest earnings report isn’t just a financial win it’s a strategic signal. The company’s blockbuster sales of Zepbound and Mounjaro reflect a seismic shift in the healthcare landscape, where GLP-1 weight-loss drugs are rapidly becoming a multi-billion-dollar category. With revenue up 54% year-over-year and a raised full-year outlook, Lilly is positioning itself as a dominant force in a market projected to be worth tens of billions in the coming years.

For investors, this matters because:

• Lilly is capturing early leadership in a high-growth therapeutic segment.
• Its aggressive expansion strategy signals long-term revenue durability.
• The GLP-1 boom could reshape pharma valuations, with Lilly at the center.

Eli Lilly has raised its full-year financial outlook following a surge in demand for its weight-loss drugs Zepbound and Mounjaro. The company now expects:

• Revenue: $63–$63.5 billion (up from $60–$62 billion)
• Adjusted EPS: $23–$23.70 (up from $21.75–$23)

This bullish revision reflects the continued strength of Lilly’s GLP-1 portfolio, which has become a cornerstone of its growth strategy.

Adding to the momentum, Lilly announced a new partnership with Walmart to distribute Zepbound directly to patients. Starting mid-next month, the drug will be available for pickup at Walmart pharmacies, expanding access and reinforcing Lilly’s retail footprint in the obesity treatment market.

Despite these gains, Eli Lilly shares are up just 5% year-to-date, trailing the S&P 500’s 17% advance. The modest performance suggests that investors may be waiting for further confirmation of long-term growth durability before bidding the stock higher.